- Home
- FGEN vs RADX Comparison
FGEN vs RADX Comparison
Compare FGEN & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- RADX
- Stock Information
- Founded
- FGEN 1993
- RADX 2021
- Country
- FGEN United States
- RADX Australia
- Employees
- FGEN N/A
- RADX N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- FGEN Health Care
- RADX
- Exchange
- FGEN Nasdaq
- RADX NYSE
- Market Cap
- FGEN 33.5M
- RADX 32.5M
- IPO Year
- FGEN 2014
- RADX N/A
- Fundamental
- Price
- FGEN $7.26
- RADX $4.25
- Analyst Decision
- FGEN Strong Buy
- RADX Strong Buy
- Analyst Count
- FGEN 1
- RADX 2
- Target Price
- FGEN $250.00
- RADX $13.50
- AVG Volume (30 Days)
- FGEN 74.1K
- RADX 22.4K
- Earning Date
- FGEN 08-05-2025
- RADX 02-26-2025
- Dividend Yield
- FGEN N/A
- RADX N/A
- EPS Growth
- FGEN N/A
- RADX N/A
- EPS
- FGEN N/A
- RADX N/A
- Revenue
- FGEN $6,996,000.00
- RADX $204,609.00
- Revenue This Year
- FGEN N/A
- RADX N/A
- Revenue Next Year
- FGEN N/A
- RADX N/A
- P/E Ratio
- FGEN N/A
- RADX N/A
- Revenue Growth
- FGEN N/A
- RADX N/A
- 52 Week Low
- FGEN $4.50
- RADX $3.50
- 52 Week High
- FGEN $38.25
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- FGEN 60.54
- RADX N/A
- Support Level
- FGEN $5.37
- RADX N/A
- Resistance Level
- FGEN $5.73
- RADX N/A
- Average True Range (ATR)
- FGEN 0.49
- RADX 0.00
- MACD
- FGEN 0.27
- RADX 0.00
- Stochastic Oscillator
- FGEN 83.80
- RADX 0.00
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.